Overview: SCA1 ATXN1 Mutation TestIntroduction: The SCA1 ATXN1 Mutation Test detects ATXN1 mutations to diagnose spinocerebellar ataxia, causing coordination issues. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected spinocerebellar ataxia type 1.
Other Names: SCA1 Mutation Assay, ATXN1 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: SCA1 testing began in the 1990s with ATXN1 gene discovery. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects ATXN1 mutations to diagnose spinocerebellar ataxia, guides treatment, and evaluates patients with coordination issues.
Test Parameters: 1. ATXN1 Gene Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of coordination issues or neurological symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document coordination issues, ataxia, or family history of spinocerebellar ataxia. Include current medications, especially anticonvulsants.
Consent: Written consent required, detailing the tests purpose, spinocerebellar ataxia implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect ATXN1 trinucleotide repeat expansions. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for SCA1 diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Positive ATXN1 mutation confirms SCA1, guiding supportive therapies or genetic counseling. Negative results may require other SCA gene testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, neurological exam, or other SCA gene tests to confirm spinocerebellar ataxia diagnosis.
Test Limitations: Specific to ATXN1; other SCA types may be missed. Clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Spinocerebellar Ataxia Guidelines, 2023; Neurology, Orr HT, 2022.
